Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.85 |
| ▸ | GAK | O14976 | 3/20 | 0.85 |
| ▸ | KDR | P35968 | 3/20 | 0.85 |
| ▸ | FLT1 | P17948 | 2/20 | 0.85 |
| ▸ | ILK | Q13418 | 2/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.85 |
| ▸ | BUB1 | O43683 | 2/20 | 0.85 |
| ▸ | STK10 | O94804 | 2/20 | 0.85 |
| ▸ | ABL1 | P00519 | 2/20 | 0.85 |
| ▸ | LCK | P06239 | 2/20 | 0.85 |
| ▸ | LYN | P07948 | 2/20 | 0.85 |
| ▸ | RET | P07949 | 2/20 | 0.85 |
| ▸ | SRC | P12931 | 2/20 | 0.85 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.85 |
| ▸ | FECH | P22830 | 2/20 | 0.85 |
| ▸ | FLT3 | P36888 | 2/20 | 0.85 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.85 |
| ▸ | PLK4 | O00444 | 1/20 | 0.85 |
| ▸ | CIT | O14578 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348479 | 0.96 | EGFR (0.85) | EGFRERBB2GAKKDRFLT1 | |
| SCHEMBL30052378 | 0.96 | EGFR (0.85) | EGFRERBB2GAKKDRFLT1 | |
| Hydrochloric Acid SCHEMBL1507512 | 0.95 | EGFR (0.85) | EGFRERBB2GAKKDRFLT1 | |
| Erlotinib SCHEMBL29120903 | 0.92 | EGFR (0.96) | EGFRERBB2GAKKDRFLT1 | |
| Erlotinib SCHEMBL8413 | 0.92 | EGFR (1.00) | EGFRERBB2GAKKDRFLT1 | |
| Erlotinib SCHEMBL29351329 | 0.92 | EGFR (1.00) | EGFRERBB2GAKKDRFLT1 | |
| Erlotinib SCHEMBL3667407 | 0.92 | EGFR (1.00) | EGFRERBB2GAKKDRFLT1 | |
| Erlotinib SCHEMBL30362833 | 0.92 | EGFR (1.00) | EGFRERBB2GAKKDRFLT1 | |
| Erlotinib SCHEMBL28471753 | 0.91 | EGFR (0.94) | EGFRERBB2GAKKDRFLT1 | |
| Erlotinib SCHEMBL16767632 | 0.91 | EGFR (1.00) | EGFRERBB2GAKKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111265668-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | claimed |
| CN-111265668-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-06-12 | — | — | CN | disclosed |
| EP-3103799-A1 | QUINAZOLINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9452220-B2 | Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9452220-B2 | Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-27 | — | — | US | disclosed |
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-06-23 | — | — | US | disclosed |
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-06-23 | — | — | US | disclosed |
| EP-2163546-B1 | Quinazoline derivatives | PFIZER PROD INC (US) | 2016-06-01 | — | — | EP | disclosed |
| CN-103483275-B | The coupling compound of NSAID class anti-inflammatory analgesic medicine and EGFR kinase inhibitor and synthetic method thereof and application | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2015-09-02 | — | — | CN | disclosed |
| CN-103483275-A | Coupling compound of NSAID anti-inflammatory pain killers and EGFR kinase inhibitor and synthetic method and application of coupling compound | GUANGZHOU INST BIOMED & HEALTH | 2014-01-01 | — | — | CN | disclosed |
| EP-2295415-A1 | Quinazoline derivatives | OSI Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2163546-A1 | Quinazoline derivatives | Pfizer Products Incorporated (US) | 2010-03-17 | — | — | EP | disclosed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| WO-2009070328-A1 | MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | EGFR, CHUK, ERBB2 | EGFR 1/4885ERBB2 3/4885GAK 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.